-
1
-
-
20344393896
-
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
-
Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., Leversha M.A., Jeffrey P.D., Desantis D., Singer S., Brennan M.F., Maki R.G., DeMatteo R.P. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 2005, 11:4182-4190.
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 4182-4190
-
-
Antonescu, C.R.1
Besmer, P.2
Guo, T.3
Arkun, K.4
Hom, G.5
Koryotowski, B.6
Leversha, M.A.7
Jeffrey, P.D.8
Desantis, D.9
Singer, S.10
Brennan, M.F.11
Maki, R.G.12
DeMatteo, R.P.13
-
2
-
-
26944447953
-
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia
-
Goemans B.F., Zwaan C.M., Miller M., Zimmermann M., Harlow A., Meshinchi S., Loonen A.H., Hählen K., Reinhardt D., Creutzig U., Kaspers G.J., Heinrich M.C. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
-
(2005)
Leukemia
, vol.19
, pp. 1536-1542
-
-
Goemans, B.F.1
Zwaan, C.M.2
Miller, M.3
Zimmermann, M.4
Harlow, A.5
Meshinchi, S.6
Loonen, A.H.7
Hählen, K.8
Reinhardt, D.9
Creutzig, U.10
Kaspers, G.J.11
Heinrich, M.C.12
-
3
-
-
57149112342
-
Masitinib is safe and effective for the treatment of canine mast cell tumors
-
Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. J. Vet. Intern. Med. 2008, 22:1301-1309.
-
(2008)
J. Vet. Intern. Med.
, vol.22
, pp. 1301-1309
-
-
Hahn, K.A.1
Ogilvie, G.2
Rusk, T.3
Devauchelle, P.4
Leblanc, A.5
Legendre, A.6
Powers, B.7
Leventhal, P.S.8
Kinet, J.P.9
Palmerini, F.10
Dubreuil, P.11
Moussy, A.12
Hermine, O.13
-
4
-
-
47849096884
-
Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs
-
Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., Setoguchi A., Ono K., Washizu T., Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J. Vet. Intern. Med. 2008, 22:985-988.
-
(2008)
J. Vet. Intern. Med.
, vol.22
, pp. 985-988
-
-
Isotani, M.1
Ishida, N.2
Tominaga, M.3
Tamura, K.4
Yagihara, H.5
Ochi, S.6
Kato, R.7
Kobayashi, T.8
Fujita, M.9
Fujino, Y.10
Setoguchi, A.11
Ono, K.12
Washizu, T.13
Bonkobara, M.14
-
5
-
-
72249097498
-
Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours
-
Isotani M., Yamada O., Lachowicz J.L., Tamura K., Yagihara H., Fujino Y., Ono K., Washizu T., Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br. J. Haematol. 2010, 148:144-153.
-
(2010)
Br. J. Haematol.
, vol.148
, pp. 144-153
-
-
Isotani, M.1
Yamada, O.2
Lachowicz, J.L.3
Tamura, K.4
Yagihara, H.5
Fujino, Y.6
Ono, K.7
Washizu, T.8
Bonkobara, M.9
-
6
-
-
51649105768
-
Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors
-
Letard S., Yang Y., Hanssens K., Palmérini F., Leventhal P.S., Guéry S., Moussy A., Kinet J.P., Hermine O., Dubreuil P. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol. Cancer Res. 2008, 6:1137-1145.
-
(2008)
Mol. Cancer Res.
, vol.6
, pp. 1137-1145
-
-
Letard, S.1
Yang, Y.2
Hanssens, K.3
Palmérini, F.4
Leventhal, P.S.5
Guéry, S.6
Moussy, A.7
Kinet, J.P.8
Hermine, O.9
Dubreuil, P.10
-
7
-
-
0032905427
-
Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit
-
London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 1999, 27:689-697.
-
(1999)
Exp. Hematol.
, vol.27
, pp. 689-697
-
-
London, C.A.1
Galli, S.J.2
Yuuki, T.3
Hu, Z.Q.4
Helfand, S.C.5
Geissler, E.N.6
-
8
-
-
66649106646
-
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision
-
London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., Bergman P.J., Couto G.C., Mauldin G.N., Michels G.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 2009, 15:3856-3865.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 3856-3865
-
-
London, C.A.1
Malpas, P.B.2
Wood-Follis, S.L.3
Boucher, J.F.4
Rusk, A.W.5
Rosenberg, M.P.6
Henry, C.J.7
Mitchener, K.L.8
Klein, M.K.9
Hintermeister, J.G.10
Bergman, P.J.11
Couto, G.C.12
Mauldin, G.N.13
Michels, G.M.14
-
9
-
-
42249108361
-
KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors
-
Tabone-Eglinger S., Subra F., El Sayadi H., Alberti L., Tabone E., Michot J.P., Théou-Anton N., Lemoine A., Blay J.Y., Emile J.F. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin. Cancer. Res. 2008, 14:2285-2294.
-
(2008)
Clin. Cancer. Res.
, vol.14
, pp. 2285-2294
-
-
Tabone-Eglinger, S.1
Subra, F.2
El Sayadi, H.3
Alberti, L.4
Tabone, E.5
Michot, J.P.6
Théou-Anton, N.7
Lemoine, A.8
Blay, J.Y.9
Emile, J.F.10
-
10
-
-
77956268346
-
Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines
-
Takeuchi Y., Fujino Y., Watanabe M., Nakagawa T., Ohno K., Sasaki N., Sugano S., Tsujimoto H. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. Vet. Immunol. Immunopathol. 2010, 137:208-216.
-
(2010)
Vet. Immunol. Immunopathol.
, vol.137
, pp. 208-216
-
-
Takeuchi, Y.1
Fujino, Y.2
Watanabe, M.3
Nakagawa, T.4
Ohno, K.5
Sasaki, N.6
Sugano, S.7
Tsujimoto, H.8
-
11
-
-
33845751024
-
Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling
-
Xiang Z., Kreisel F., Cain J., Colson A., Tomasson M.H. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol. Cell. Biol. 2007, 27:267-282.
-
(2007)
Mol. Cell. Biol.
, vol.27
, pp. 267-282
-
-
Xiang, Z.1
Kreisel, F.2
Cain, J.3
Colson, A.4
Tomasson, M.H.5
|